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The live chimeric porcine circovirus type 2 (PCV2) vaccine with the capsid gene of the emerging subtype 2b
cloned in the genomic backbone of the nonpathogenic PCV1 is attenuated in vivo and induces protective
immunity against PCV2. To further determine the safety and efficacy of this experimental vaccine, we tested for
evidence of pig-to-pig transmission by commingling nonvaccinated and vaccinated pigs, determined potential
upregulation by simultaneous vaccination and infection with porcine parvovirus (PPV) and porcine reproduc-
tive and respiratory syndrome virus (PRRSV), and determined vaccine efficacy by challenging pigs 4 weeks
after vaccination with PCV2b, PRRSV, and PPV. Forty-six 21-day-old, PCV2-naïve pigs were randomly as-
signed to one of six groups. Twenty-nine of 46 pigs were challenged with PCV2b, PRRSV, and PPV at day 28,
8/46 remained nonvaccinated and nonchallenged and served as negative controls, and 9/46 remained nonchal-
lenged and served as vaccination controls. All animals were necropsied at day 49. PCV1-PCV2 viremia was
detected in nonvaccinated contact pigs commingled with vaccinated pigs, indicating pig-to-pig transmission;
however, PCV1-PCV2 DNA levels remained low in all vaccinated and contact pigs regardless of concurrent
infection. Finally, vaccination 28 days before challenge resulted in significantly (P < 0.05) decreased amounts
of PCV2 in tissues and sera and significantly (P < 0.05) reduced macroscopic and microscopic lesions. The
results of this study indicate that the experimental live-attenuated chimeric PCV2 vaccine, although trans-
missible to contact pigs, remains attenuated in pigs concurrently infected with PRRSV and PPV and induces
protective immunity against PCV2b when it is administered 28 days before PCV2 exposure.
Porcine circoviruses (PCVs) comprise a group of small, non-
enveloped, single-stranded circular DNA viruses (44) which
can be divided into two major genotypes: nonpathogenic PCV
type 1 (PCV1) and pathogenic PCV type 2 (PCV2) (1). More-
over, PCV2 can be subdivided into two major subtypes, com-
monly referred to as PCV2a and PCV2b (6, 40), from which
the latter subtype (PCV2b) emerged recently in the United
States and Canada. Porcine circoviruses contain two major
open reading frames (ORFs) oriented in opposite directions
which encode proteins associated with replication (ORF1) and
the capsid (ORF2) (21, 25).
Commercial PCV2 vaccines for use in growing pigs and
breeding-age animals became available in North America in
2006, and at least four commercial vaccines are now available.
All products available to date are inactivated or subunit vac-
cines based on the PCV2a subtype, even though the currently
dominant strain circulating in the field is PCV2b. Studies have
shown that PCV2a and PCV2b are cross-protective (12, 34).
Under experimental (12, 29, 31, 32) and field (8, 17, 19) con-
ditions, the current inactivated or subunit PCV2 vaccines have
been shown to be extremely effective in reducing PCV2
viremia, PCV2-associated microscopic lesions, and PCV2-as-
sociated morbidity and mortality (12, 29, 31, 32). In addition,
vaccinated pigs were shown to have improved average daily
gain, increased percentage of lean meat yield, improved feed
conversion, and decreased back fat depth, and typically the
medication costs in vaccinated herds were reduced (8, 17, 19).
Several of the commercially available killed PCV2 vaccines
require 1 or 2 doses of intramuscular administration (30).
An experimental live chimeric PCV1-PCV2a (PCV1-2a)
vaccine with the capsid gene of PCV2a cloned in the backbone
of the nonpathogenic PCV1 has been developed and shown to
be nonpathogenic in the growing-pig model (11). An inacti-
vated version of the live vaccine, Suvaxyn PCV2 (Fort Dodge
Animal Health, Inc.), has previously been licensed and was
commercially introduced to the North American pig popula-
tion in 2006 (30). Both the inactivated and the live-attenuated
PCV2 vaccines were demonstrated to be very effective and
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induced protective immunity in the singular PCV2-challenge
model (10, 31, 33, 43). It has been shown that the live chimeric
PCV1-2a vaccine virus is genetically stable when it is serially
passaged in cell culture as well as in pigs (14). Interestingly, in
2008 a chimeric PCV1-2a was isolated from cases of acute
outbreaks of porcine reproductive and respiratory syndrome
(PRRS) in Canada (13). The authors speculated that the iden-
tified PCV1-2 may have originated from the chimeric killed
vaccine widely used in the affected areas. Alternatively, forma-
tion of PCV1-2a may have been due to a natural recombina-
tion event between PCV1 and PCV2 (13).
Globally, indications are that PCV2b is by far the most
common strain associated with PCV2-associated diseases
(PCVADs); however, all current commercial vaccines, includ-
ing the experimental live PCV2 vaccine described above, are
based on the PCV2a subtype. Thus, in an effort to continuously
improve existing products, it seems important to evaluate a
PCV2 vaccine that is based upon the predominant 2b subtype.
Recently, we succeeded in developing a live-attenuated chi-
meric PCV1-2b vaccine and have shown that the novel
PCV1-2b vaccine virus is attenuated and induces homologous
and heterologous immunity against both PCV2b and PCV2a
subtypes (4), making it a promising candidate as a live-atten-
uated vaccine against both PCV2b and PCV2a. However, be-
fore a live-attenuated vaccine can be introduced to the pig
market, it is of particular importance to further determine its
safety. It has been well documented that concurrent infections
of PCV2 with other swine pathogens such as PRRS virus
(PRRSV) (3, 16, 39), porcine parvovirus (PPV) (2, 20), swine
torque teno virus (TTV) (7), or Mycoplasma hyopneumoniae
(35) enhance PCV2 replication and PCVAD. The conse-
quences of concurrent infections with the chimeric PCV1-2b
vaccine virus with other pathogens are unknown. Therefore, it
is of paramount importance to make sure that the live PCV2
chimeric vaccine virus is safe in vaccinated pigs coinfected with
other common swine pathogens.
The objectives of this study were to determine the (i) pos-
sible horizontal spread (objective 1), (ii) safety (objective 2),
and (iii) efficacy (objective 3) of a chimeric PCV1-2b vaccine in
a PCV2-PRRSV-PPV triple-challenge model. For objective 1,
nonvaccinated contact pigs were commingled with vaccinated
pigs to determine if the live chimeric PCV2 vaccine was trans-
mitted to nonvaccinated animals. For objective 2, pigs were
vaccinated with the PCV1-2b vaccine and on the same day
infected with PRRSV and PPV, two pathogens that are en-
demic in the pig population and that have both been shown to
enhance PCV2 replication and disease. For objective 3, pigs
were vaccinated with the PCV1-2 vaccine and challenged with
PCV2b, PPV, and PRRSV at 28 days after vaccination, and
protection against PCV2 infection was measured by determin-
ing the presence and degree of PCV2 viremia and PCV2-
associated lesions.
MATERIALS AND METHODS
Chimeric PCV1-2b vaccine virus. The chimeric PCV1-2b vaccine virus was
created by cloning the capsid gene of the new PCV2b subtype into the genomic
backbone of the nonpathogenic PCV1, and it was previously demonstrated to be
attenuated and to induce protective and cross-protective immunity against
PCV2a and PCV2b (4). A subclone of the PK-15 cell line that is free of PCV1
contamination was used for the generation of PCV1-2b vaccine virus stocks as
described previously (4, 9, 10). The 50% tissue culture infective dose (TCID50)
per ml was calculated according to the method of Reed and Muench. The
PCV1-2b chimeric vaccine virus stock had an infectious titer of 104 TCID50s per
ml. Each pig received 4.5 ml of the vaccine virus stock (2.5 ml intranasally and 2
ml intramuscularly into the right neck area). The reason for using intranasal and
intramuscular routes in this small-scale study was to ensure equal exposure of all
pigs to the live chimeric PCV2 vaccine and to activate both the mucosal and
systemic immune responses.
Animals, housing, and experimental design. The experimental protocol was
approved by the Iowa State University Institutional Animal Care and Use Com-
mittee. Forty-six pigs were obtained from a commercial swine herd free of PCV2,
PRRSV, swine influenza virus, and PPV as determined by routine serology. At
arrival, the 46 pigs were randomly divided (off the truck by gate cut) into six
treatment groups and five rooms as outlined in Table 1. Each room contained
three raised wire decks 2.5 by 3.6 m equipped with one nipple drinker and one
self-feeder. At day 0 (when the pigs were approximately 21 days of age), pigs in
group Vac-0 and group Vac-0–PCV2 were each vaccinated with approximately
4.5  104 TCID50s of the PCV1-2b vaccine by intranasal (2.5 ml) and intramus-
cular (2 ml) injection (20-gauge needle, right neck area). At day 3, the three
nonvaccinated pigs in the contact-PCV2 group were moved into the same room
as the group Vac-0–PCV2 pigs and commingled at a ratio of three vaccinated
(Vac-0–PCV2) pigs to one nonvaccinated contact-PCV2 pig in each pen. At day
28, group Vac-28–PCV2 pigs were each inoculated with the PCV1-2b vaccine
intranasally and intramuscularly as described above. All pigs in the positive-
control, Vac-0–PCV2, contact-PCV2, and Vac-28–PCV2 groups were challenged
with PCV2b, PRRSV, and PPV at trial day 28. Throughout the experiment, the
pigs were weighed and bled weekly. After challenge, the pigs were monitored
daily for clinical signs of disease. At trial day 49 (21 days after PCV2-PRRSV-
PPV challenge), all pigs were necropsied by a pathologist blinded to treatment
group. Various tissues were collected during the necropsy and evaluated in a
blinded fashion for severity and characteristics of macroscopic and microscopic
lesions as described previously (35).
PCV2b-PRRSV-PPV challenge. PCV2b isolate NC-16845 was used for the
challenge and was propagated on PK-15 cells as previously described (34). The
PCV2b challenge virus stock had an infectious titer of 104.0 TCID50s per ml.
PRRSV isolate ATCC VR2385 was propagated on MARC-145 cells. The 7th
passage of the virus, with a titer of 1  105 to 1  106 focus-forming units/ml,
which corresponds to approximately 1  105 TCID50s/ml (18), was used as the
challenge stock. PPV strain NADL-8 was isolated from fetal porcine kidney cells
from a naturally infected pig in 1977 in Perry, IA (22). In this study, the challenge
virus stock was PPV from passage 4 in pigs (10% tissue homogenate suspension
containing lungs of aborted fetuses in minimal essential medium) from the year
1982 and was used at an approximate titer of 104.9 TCID50s. Each pig in the
challenged groups (Table 1) received 2 ml of the PCV2b stock intramuscularly
into the right neck. In addition, each pig also received 2 ml PCV2b, 3 ml PRRSV,
and 1 ml PPV intranasally by slowly dripping each inoculum into both nostrils.
Successful challenge using this model was demonstrated by seroconversion, de-
tected by enzyme-linked immunosorbent assay (ELISA), and viremia, detected
by real-time PCR in the unvaccinated positive-control group.
Serology. Blood samples were collected upon arrival of the pigs and weekly
thereafter until necropsy at trial day 49. All serum samples were tested by an
ORF2-based anti-PCV2 IgG ELISA (24). Samples were considered positive if
the calculated sample-to-positive (S/P) ratio was 0.2 or greater (24). All serum
samples collected on trial days 28, 35, 42, and 49 were also tested for the presence
of specific antibodies to PRRSV with a commercial PRRSV ELISA (HerdChek
TABLE 1. Experimental design
Group No. ofpigs
PCV1-2b vaccination
PCV2b-PRRSV-PPV
challenge, trial day
28 (age 49 days)
Trial day
0 (age
21 days)
Trial day
28 (age
49 days)
Negative controls 8   
Positive controls 8   
Vac-0 9   
Vac-0–PCV2 9   
Contact-PCV2a 3   
Vac-28–PCV2 9   
a Contact-PCV2 pigs were moved into the pens with the Vac-0–PCV2 group 3
days after PCV1-2b vaccination.
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PRRS 2XR antibody ELISA; IDEXX Laboratories, Inc. Westbrook, MA). A
hemagglutination inhibition assay for detection of PPV-specific antibodies was
performed on all serum samples on trial days 28 (challenge) and 49 (necropsy)
as previously described (23).
Clinical evaluation. Following PCV2 inoculation, the pigs were monitored
daily for clinical signs, including sneezing, lethargy, and coughing. All pigs were
weighed once per week.
Quantification of PCV2 and PCV1-2b DNA loads. DNA was extracted from
serum samples collected on trial day 0 and weekly thereafter until termination of
the study using a QIAamp DNA minikit (Qiagen, Valencia, CA). DNA extracts
were used for quantification of PCV2 genomic DNA copy numbers by real-time
PCR as described previously (36). All DNA extracts from trial days 0 to 49 were
used for quantification of the vaccine virus PCV1-2b genomic DNA copy num-
bers by a real-time PCR assay designed to differentiate PCV1-2 chimeric DNA
from both PCV2 and PCV1 DNA. A forward primer (5-TGACAGTATATCC
GAAGGTGCG-3), a reverse primer (5-GCCGAAGTGCGCTGGTAATA-
3), and a probe (5-CAL Fluor Orange 560-CGCACTTCTTTCACTTTTATA
GGATG-BHQ-3) were designed in the region spanning PCV2 ORF2
(GenBank accession no. AF264042) and PCV1 ORF1 (GenBank accession no.
U49186) using the primer-probe test tool of Primer Express software, version 3.0
(Applied Biosystems, Foster City, CA). The presence of sequence dissimilarity in
the regions allowed PCV1-2b chimeric DNA to be distinguished from both PCV2
and PCV1 DNA. The real-time PCR mixture consisted of a total volume of 25
l containing 12.5 l of TaqMan universal PCR master mix (Applied Biosys-
tems), 1 l of each forward and reverse primer (final concentration, 400 nM), 0.5
l TaqMan probe (final concentration, 200 nM), 7.5 l nuclease-free water, and
2.5 l extracted DNA. The reactions were carried out in a 7500 Fast real-time
PCR system (Applied Biosystems). The PCR cycling parameters were 2 min at
50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C, 30 s at 55°C, and
1 min at 60°C. Samples were considered negative when there was no observed
threshold cycle (CT) value during the 40 amplification cycles. Five progressive
1:10 dilutions of a known copy number (8.13  109 to 8.13  104 copies/ml) of
the PCV1-2b chimeric DNA clone in the pSK vector were used to generate the
standard curve. The specificity of the primers and probe was determined by using
2.5 l PCV1, PCV2a, and PCV2b DNA extracted from virus preparations and
animals infected with PCV2a or PCV2b as described above. No cross-reactions
were observed in the real-time PCR (data not shown).
PRRSV RNA quantification. Total RNAs from the serum samples obtained on
trial days 35, 42, and 49 were isolated using a QIAamp viral RNA minikit
(Qiagen) according to the manufacturer’s instructions. Quantitative reverse tran-
scription-PCR (Q-RT-PCR) was performed using TaqMan PRRSV reagents and
controls (Applied Biosystems) in a 25-l volume with 12.5 l 2 multiplex
RT-PCR buffer, 2.5 l 10 PRRSV primer-probe mix, 1.25 l 20 multiplex
enzyme mix, 0.75 l nuclease-free water, and 8 l of PRRSV RNA standard or
extracted RNA. The reaction mixture was incubated at 45°C for 10 min and 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 70 s.
PPV DNA quantification. DNA was extracted from the serum samples at trial
day 49 using a QIAamp DNA blood minikit (Qiagen) and tested by a quantita-
tive PPV real-time PCR. A forward primer (5-CAGAATCAGCAACCTCACC
A-3), a reverse primer (5-GCTGCTGGTGTGTATGGAAG-3), and a probe
(5–6-carboxyfluorescein–TGCAAGCTTAATGGTCGCACTAGACA–black hole
quencher–3) were designed to amplify the VP2 gene of PPV. The reaction was
performed in a 25-l mixture with 12.5 l 2 PCR master mix (Applied Bio-
systems), 1 l of each forward and reverse primer (final concentration, 500 nM),
0.5 l TaqMan probe (final concentration, 200 nM), 7.5 l nuclease-free water,
and 2.5 l extracted DNA. The amplification was performed at 50°C for 2 min
and 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
Serial dilutions of a recombinant vector PCR2.1 (Invitrogen, Carlsbad, CA)
containing the PPV VP2 gene were used to obtain a standard curve.
Necropsy. All pigs were euthanized by intravenous pentobarbital sodium
(Fatal-Plus; Vortech Pharmaceutical, LTD, Dearborn, MI) overdose and nec-
ropsied on trial day 49. The total amount of macroscopic lung lesions (range, 0
to 100%) was estimated and scored as previously described (15). Additionally,
the sizes of lymph nodes (tracheobronchiolar, mediastinal, and superficial ingui-
nal), ranging from 0 (normal) to 3 (four times the normal size), were estimated
and recorded (27). Sections of lymph nodes (superficial inguinal, mediastinal,
tracheobronchial, mesenteric, and external iliac), tonsil, thymus, ileum, kidney,
colon, spleen, and liver were collected at necropsy, fixed in 10% neutral-buffered
formalin, and routinely processed for histological examination.
Histopathology. Microscopic lesions were evaluated by two veterinary pathol-
ogists (T.O., P.G.H.) blinded to the treatment group. Sections were scored for
the presence and severity of interstitial pneumonia, with scores ranging from 0
(normal) to 6 (severe diffuse) (15). Sections of heart, liver, kidney, ileum, and
colon were evaluated for the presence of lymphohistiocytic inflammation and
scored from 0 (none) to 3 (severe). Lymphoid tissues, including lymph nodes
(tracheobronchiolar, mesenteric, mediastinal, superficial inguinal, and external
iliac), tonsil, and spleen were evaluated for the presence of lymphoid depletion,
with scores ranging from 0 (normal) to 3 (severe), and histiocytic inflammation
and replacement of follicles, with scores ranging from 0 (normal) to 3 (severe)
(35). The overall microscopic lymphoid lesion score, which consists of the scores
for lymphoid depletion, histiocytic inflammation, and the presence of PCV2
antigen in lymphoid tissues, was calculated as previously described and ranged
from 0 (normal) to 9 (severe) (35). Briefly, the scores (lesions and PCV2 immu-
nohistochemistry [IHC]) of seven lymphoid tissues ([lymph node pool]  4,
tracheobronchial lymph node, spleen, and tonsil) were added up and divided by
7. The lymph node pool consisted of superficial inguinal, external iliac, medias-
tinal, and mesenteric lymph nodes. The mean treatment group lymphoid score
was calculated and compared between groups. Pigs were grouped into four
categories on the basis of overall microscopic lymphoid lesion scores: 0 (normal),
1 to 3 (mild), 4 to 6 (moderate), and 7 to 9 (severe) (35).
IHC. Detection of PCV2-specific antigen was performed on selected formalin-
fixed and paraffin-embedded sections of lymph nodes (superficial inguinal, me-
diastinal, tracheobronchial, external iliac, and mesenteric), tonsil, spleen, and
thymus using a rabbit polyclonal antiserum specific for PCV2 capsid protein (42).
PCV2 antigen scoring was done by a veterinary pathologist (T.O.) blinded to
treatment. Scores ranged from 0 (no signal) to 3 (more than 50% of the lymphoid
follicles contain cells with PCV2 antigen staining) (35).
Statistical analysis. Summary statistics were calculated to assess the overall
quality of the data. Analysis of variance (ANOVA) was used for cross-sectional
assessment of the average daily weight gain and repeated continuous measures.
The significance level was set for a P value of 0.05, followed by pairwise testing
using the Tukey-Kramer adjustments to identify the groups that were different.
Nonrepeated measures of necropsy and histopathology data were assessed using
nonparametric Kruskal-Wallis ANOVA. If a nonparametric ANOVA test was
significant (P  0.05), then Wilcoxon tests were used to assess the differences of
pairs of groups. Differences in incidence were evaluated by using Fisher’s exact
test. Statistical analysis was performed using JMP software (version 8.0.0; SAS
Institute Inc., Cary, NC).
RESULTS
Clinical presentation. Clinical disease was not observed in
any of the pigs after PCV1-2b vaccination, and none of the pigs
had visible reactions (redness, swelling, higher temperature) at
the vaccination site. After PCV2, PRRSV, and PPV challenge
at trial day 28, pigs in the positive-control, Vac-0–PCV2, con-
tact-PCV2, and Vac-28–PCV2 groups developed mild respira-
tory disease characterized by sneezing and occasional clear
nasal discharge. The average daily weight gain was not differ-
ent among groups before or after challenge (data not shown).
However, individual pigs in the positive-control group and the
Vac-28–PCV2 group had a decreased weight gain after chal-
lenge. Between trial days 35 and 42, 1/8 positive-control pigs
had decreased weight gain (0.3 lb), became lethargic, and died
at trial day 45 (18 days postchallenge). Between trial days 42
and 49, 3/9 Vac-28–PCV2 pigs lost weight (0.4, 0.6, and
0.6 lb, respectively).
Macroscopic lesions. At necropsy, the majority of the chal-
lenged pigs had macroscopic lung lesions characterized by mul-
tifocal-to-diffuse, mottled-tan areas of consolidation and dif-
fuse failure of the lungs to collapse. The incidence of pigs with
lung lesions was 0/8 negative controls, 7/8 unvaccinated posi-
tive controls, 2/9 Vac-0 pigs, 7/9 Vac-0–PCV2 pigs, 3/3 contact-
PCV2 pigs, and 9/9 Vac-28–PCV2 pigs. The mean group lung
lesion scores are summarized in Table 2. Unvaccinated positive
controls and Vac-28–PCV2 pigs had significantly (P  0.05)
higher mean gross lung lesion scores than all other groups. The
majority of the pigs also had evidence of lymph node enlarge-
ment up to 3 times the normal size (2/8 negative controls, 7/8
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unvaccinated positive controls, 1/9 Vac-0 pigs, 8/9 Vac-0–
PCV2 pigs, 3/3 contact-PCV2 pigs, and 9/9 Vac-28—PCV2
pigs).
Serological response. (i) Anti-PCV2-IgG antibody response.
The negative-control piglets remained negative for anti-PCV2
antibodies through the end of the study (Table 3; Fig. 1),
whereas the positive-control piglets began to seroconvert at 14
days postchallenge (trial day 42). Pigs vaccinated with
PCV1-2b on trial day 0 (Vac-0 and Vac-0–PCV2) serocon-
verted between trial days 14 and 28. The nonvaccinated con-
tact-PCV2 pigs seroconverted between trial days 35 and 42
after PCV2 challenge (Table 3).
(ii) Anti-PRRSV antibody response. All pigs were negative
for anti-PRRSV antibodies prior to initiation of the study and
at trial day 35. Negative controls and Vac-0 pigs remained
PRRSV seronegative for the remainder of the study. At trial
day 42, 3/7 unvaccinated positive controls, 9/9 Vac-0–PCV2
pigs, 3/3 contact-PCV2 pigs, and 7/9 Vac-28–PCV2 pigs were
positive for anti-PRRSV antibodies. At trial day 49, all pigs
inoculated with PRRSV had seroconverted to PRRSV, except
for 1/9 Vac-28–PCV2 pigs (data not shown).
(iii) Anti-PPV antibody response. All pigs were negative for
anti-PPV antibodies prior to and at trial day 28. At trial day 42,
0/8 negative controls, 7/7 unvaccinated positive controls, 9/9
Vac-0–PCV2 pigs, 2/3 contact-PCV2 pigs, and 9/9 Vac-28–
PCV2 pigs were positive for anti-PPV antibodies (data not
shown).
Prevalence and PCV2 DNA load in serum. The group mean
log10 numbers of PCV2 DNA genomic copies per ml of serum
are summarized in Table 3. PCV2 DNA was not detected in
any pig at the day of challenge (trial day 28) or in pigs in the
negative-control group at any time point. Figure 2 shows a
comparison of the PCV2 DNA load in sera of the pigs chal-
lenged with PCV2 (unvaccinated positive controls, Vac-0–
PCV2, contact-PCV2, Vac-28–PCV2). While the PCV2 DNA
load in serum was not different between the unvaccinated
positive controls and the Vac-28–PCV2 pigs, it was signifi-
cantly (P  0.05) higher in the Vac-28–PCV2 pigs than in the
Vac-0–PCV2 and contact-PCV2 groups (Fig. 2).
TABLE 2. Macroscopic and microscopic lung lesions and
prevalence of PCV2 and PRRSV antigen in lung tissuesa
Group No. ofpigs
Lung lesion score
Prevalence of
antigen (no.
of pigs with
antigen/total
no. in group)
Macroscopic Microscopic PCV2 PRRSV
Negative controls 8 0.0  0.0A 1.4  0.2A,B 0/8 0/8
Positive controls 8 46.9  8.1B 4.1  0.3C 2/8 3/8
Vac-0 9 1.8  1.4A 0.6  0.2B 0/9 0/9
Vac-0–PCV2 9 18.2  4.9A 2.6  0.4A 0/9 1/9
Contact-PCV2 3 13.3  6.2A 2.7  0.3A,C 0/3 1/3
Vac-28–PCV2 9 47.2  8.4B 3.8  0.2C 2/9 2/9
a Data represent group means  standard errors for macroscopic lung lesions
(with a range of 0 to 100% of the lung surface affected by lesions) and micro-
scopic lung lesions (with a range of 0 normal	 to 6 severe diffuse interstitial
pneumonia) and prevalence of PCV2 and PRRSV antigen in lung tissues deter-
mined by immunohistochemical stains at the time of necropsy (trial day 49, 21
days after PCV2b-PRRSV-PPV challenge). Different superscripts within col-
umns (A, B, C) indicate significant (P  0.05) differences between groups.
TABLE 3. Prevalence of PCV1-2b DNA, PCV2b DNA, and anti-PCV2 IgG antibodies and group mean log10 numbers of PCV2 DNA
genomic copies/ml serum in pigs in the different groups on different trial daysa
Group DNA or AB
Result on trial day:
0 7 14 21 28 35 42 49
Negative controls PCV1-2 DNA 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0)
PCV2 DNA 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0)
PCV2 AB 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0)
Positive controls PCV1-2 DNA 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0)
PCV2 DNA 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 8/8 (5.80) 8/8 (6.78) 7/7 (6.63)
PCV2 AB 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0) 7/8 (0.276) 7/7 (0.691)
Vac-0 PCV1-2 DNA 0/9 (0.0) 1/9 (2.91) 5/9 (3.09) 8/9 (4.01) 5/9 (3.66) 2/9 (3.24) 1/9 (3.45) 1/9 (2.88)
PCV2 DNA 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0)
PCV2 AB 0/9 (0.0) 0/9 (0.0) 3/9 (0.253) 6/9 (0.324) 9/9 (0.399) 9/9 (0.432) 9/9 (0.541) 9/9 (0.580)
Vac-0–PCV2 PCV1-2 DNA 0/9 (0.0) 2/9 (3.56) 6/9 (3.30) 6/9 (3.65) 5/9 (3.29) 1/9 (3.73) 1/9 (3.50) 1/9 (2.96)
PCV2 DNA 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 1/9 (3.05) 1/9 (3.22) 1/9 (2.90)
PCV2 AB 0/9 (0.0) 0/9 (0.0) 1/9 (0.233) 6/9 (0.324) 9/9 (0.401) 9/9 (0.454) 9/9 (0.592) 9/9 (0.638)
Contact-PCV2 PCV1-2 DNA 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 2/3 (3.40) 3/3 (3.50) 2/3 (3.54) 1/3 (2.97)
PCV2 DNA 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 3/3 (3.79) 2/3 (3.55) 2/3 (3.20)
PCV2 AB 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 0/3 (0.0) 2/3 (0.245) 3/3 (0.457) 3/3 (0.503)
Vac-28–PCV2 PCV1-2 DNA 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 6/9 (3.30) 6/9 (4.02) 2/9 (3.64)
PCV2 DNA 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 9/9 (6.39) 9/9 (6.59) 9/9 (5.61)
PCV2 AB 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 5/9 (0.0) 9/9 (0.502)
a Prevalence of PCV1-2b DNA, PCV2b DNA, and anti-PCV2 IgG antibodies (AB) in pigs in the different groups at trial days 0, 7, 14, 21, 28 (the day of
PCV2b-PRRSV-PPV challenge), 35, 42, and 49 (the day of necropsy). Data are presented as number of positive animals/total number of animals (log-transformed mean
genomic copy numbers/ml serum for PCR-positive animals or group mean S/P ratio for ELISA-positive animals). An S/P ratio equal to or greater than 0.2 was
considered positive. Positive samples are indicated in boldface.
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Prevalence and amount of PCV1-2 vaccine virus DNA in
serum. The PCV1-2 chimeric vaccine virus DNA was detected
in pigs 7 days after vaccination (Table 3). The amount of
PCV1-2 DNA was not different among treatment groups, re-
gardless of coinfection status. Two of three contact-PCV2 pigs
became PCR positive for PCV1-2 at trial day 28, and by trial
day 35, all three pigs in this group were positive for serum
PCV1-2 DNA (Table 3).
Prevalence and amount of PRRSV RNA and PPV DNA load
in serum. At trial day 49, PRRSV RNA was detected in 0/8
negative controls (log10 group mean  standard error [SE],
0.0  0.0), 6/7 unvaccinated positive controls (3.9  0.9), 0/9
Vac-0 pigs (0.0  0.0), 9/9 Vac-0–PCV2 pigs (4.6  0.3), 3/3
contact-PCV2 pigs (3.8  0.6), and 9/9 Vac-28–PCV2 pigs
(4.8  0.5). There was no significant difference in the amount
of PRRSV RNA among groups. At trial day 49, PPV DNA was
detected in 0/8 negative controls (log10 group mean  SE,
0.0  0.0), 6/7 unvaccinated positive controls (3.1  0.5), 0/9
Vac-0 pigs (0.0  0.0), 6/9 Vac-0–PCV2 pigs (2.1  0.6), 2/3
contact-PCV2 pigs (2.6  1.4), and 4/9 Vac-28–PCV2 pigs
(1.2  0.5). The positive-control pigs had significantly (P 
0.05) higher serum PPV DNA levels than Vac-28–PCV2 pigs.
Microscopic lesions and detection of intralesional PCV2
and PRRSV antigen. Microscopic lesions in lung tissues were
characterized by multifocal-to-diffuse, mild-to-moderate bron-
chointerstitial pneumonia with type 2 pneumocyte hyperplasia
and hypertrophy, thickening of alveolar septa with macro-
phages and neutrophils, and mild peribronchiolar fibrous hy-
perplasia. The group mean scores of interstitial pneumonia are
summarized in Table 2. Positive-control pigs and Vac-28–
PCV2 pigs had significantly (P  0.05) more severe lung le-
sions than pigs in the other groups except contact-PCV2 pigs.
PRRSV antigen was detected in individual pigs in all PRRSV-
inoculated groups (Table 2). The presence of PCV2 antigen in
lung tissues was limited to positive-control pigs and Vac-28–
PCV2 pigs (Table 2). The group overall lymphoid lesion scores
are summarized in Table 4. Three pigs (1/8 unvaccinated pos-
itive controls and 2/9 Vac-28–PCV2 pigs) were identified as
having severe diffuse PCV2-associated microscopic lesions
consistent with systemic PCVAD. PCV2 antigen was identified
in individual pigs in the positive-control, Vac-0, contact-PCV2,
and Vac-28–PCV2 pigs, with a higher prevalence in the unvac-
cinated positive controls and Vac-28–PCV2 pigs than all other
groups (Table 4).
DISCUSSION
It is estimated that up to 99% of the market-age pigs in the
U.S. swine population have been vaccinated against PCV2
(Edgar Diaz, Boehringer Ingelheim Vetmedica Inc., personal
communication). With the widespread use of PCV2 vaccina-
tion, cases of suspected vaccine failure are emerging, and in-
vestigations are in progress to determine the reason(s). Rea-
sons for vaccine failure can include errors in compliance with
vaccine administration protocols, such as administering the
wrong dose, using the wrong route of injection, or using het-
erologous vaccine strains with limited cross-protection. Vacci-
nation at a time when pigs are going through infection with
FIG. 1. Group mean sample-to-positive ratios and standard errors for anti-PCV2 IgG antibody response. Pigs in groups Vac-0 and Vac-0–PCV2
were PCV1-2 vaccinated at trial day 0. Pigs in groups Vac-28–PCV2 were PCV1-2 vaccinated at trial day 28. Contact-PCV2 pigs were
nonvaccinated but commingled with Vac-0–PCV2 pigs. PCV2-PRRSV-PPV challenge was done at trial day 28. A sample-to-positive ratio equal
to or greater than 0.2 was considered positive.
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other pathogens is also of concern. In many of the cases that
we have investigated, vaccine failure is often determined to be
due to actual failure to appropriately administer the vaccine to
the pigs. All currently available commercial PCV2 vaccines are
inactivated products. Many livestock producers and veterinar-
ians prefer to use modified-live vaccines if they are available
since they typically require only one dose with reduced costs.
The objectives of this study were to investigate the safety and
the efficacy of a live chimeric PCV2 vaccine based on subtype
2b in a PCV2b-PPV-PRRSV triple-coinfection model.
We have previously tested the efficacy of the PCV1-2a vac-
cine in experimental models using a single PCV2a challenge
(10, 43), and we also investigated the efficacy of the live
PCV1-2b vaccine using a single PCV2b challenge (4). Re-
cently, the ability of the live chimeric PCV2 vaccine based on
the 2b subtype to provide cross-protection against PCV2a and
PCV2b has been reported (4). Moreover, the live PCV1-2a
vaccine was recently tested and found to be efficacious in the
PCV2b-PRRSV-PPV triple-challenge model (41). In this study
we investigated the potential of pig-to-pig transmission of the
live chimeric PCV1-2b vaccine between vaccinated and non-
vaccinated naïve contact pigs and the safety of the live chimeric
PCV1-2b in vaccinated pigs simultaneously infected with
PRRSV and PPV, and we also investigated the efficacy of this
subtype 2b-based vaccine in protecting pigs against PCV2b
challenge in the PCV2-PRRSV-PPV triple-challenge model.
On the basis of the presence of severe clinical disease (1/8
positive-control pigs) consistent with systemic PCVAD and
microscopic confirmation (1/8 positive-control pigs and 3/9
Vac-28–PCV2 pigs), the challenge used in the study was suc-
cessful, and the results were similar to what has been previ-
ously described in other PCV2 coinfection studies (2, 3, 16, 20,
28, 35, 39). PCV2 replication was enhanced in nonvaccinated
pigs, as evidenced by significantly (P  0.05) more severe
macroscopic and microscopic lesions and significantly (P 
0.05) higher serum and tissue PCV2 loads in the positive-
control pigs than Vac-0–PCV2 pigs. For the PPV inoculum, we
used a pig-passaged lung homogenate. It is possible that other
unknown pathogens were propagated and present in this ho-
FIG. 2. Log-transformed group means for numbers of PCV2 DNA copies per ml serum. Pigs in groups Vac-0 and Vac-0–PCV2 were PCV1-2
vaccinated at trial day 0. Pigs in group Vac-28–PCV2 were PCV1-2 vaccinated at trial day 28. Contact-PCV2 pigs were nonvaccinated but
commingled with Vac-0–PCV2 pigs. PCV2-PRRSV-PPV challenge was done at trial day 28. Different letters (A, B, C) on a given trial day indicate
significant (P  0.05) differences between groups.
TABLE 4. Overall lymphoid lesion scores and prevalence of PCV2
antigen in lymphoid tissuesa
Group
Overall
lymphoid
lesion score
No. of pigs with the following/total no.
in group (%)
PCV2
antigen
Moderate
lesions
Severe
lesions
Negative controls 0.0  0.0A 0/8 0/8 0/8
Positive controls 3.6  0.9B,C 8/8 (100) 4/8 (50) 1/8 (12.5)
Vac-0 0.2  0.1A 2/9 (22.2) 0/9 0/9
Vac-0–PCV2 0.2  0.1A 0/9 0/9 0/9
Contact-PCV2 0.6  0.5A,B 2/3 (66.7) 0/3 0/3
Vac-28–PCV2 4.4  0.9B 8/9 (88.9) 5/9 (62.5) 2/9 (22.2)
a Data represent group mean  standard error overall lymphoid lesion score
and prevalence of PCV2 antigen in lymphoid tissues as determined by immuno-
histochemical stains at the time of necropsy (trial day 49, 21 days after PCV2b-
PRRSV-PPV challenge). Different superscripts within columns (A, B, C) indi-
cate significant (P  0.05) differences between groups.
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mogenate since it was not tested for ubiquitous viruses such as
TTV, swine lymphotropic herpesvirus, and pestivirus. How-
ever, even if this were the case, it should not have affected the
study outcome, as all challenged pigs received the same inoc-
ulum.
Our research group has previously studied the shedding and
infection dynamics of PCV2b in animals naturally and exper-
imentally infected (37, 38). With the knowledge that we gained
from these studies, the question of whether a live-attenuated
chimeric virus could also be transmitted between animals de-
veloped. Potential transmission of the live chimeric PCV2 vac-
cine was investigated by commingling vaccinated pigs with non-
vaccinated contact pigs. Specifically, we placed nonvaccinated
pigs (contact-PCV2) in the same room with pigs that had been
vaccinated with the live PCV1-2b vaccine (Vac-0–PCV2) 3
days previously. Due to funding and space restraints, we were
able to utilize only three nonvaccinated contact pigs; neverthe-
less, we found that the contact-PCV2 pigs became positive for
PCV1-2 DNA by trial day 28, and anti-PCV2 antibodies ap-
peared in these pigs immediately after PCV2 challenge and at
least 1 week prior to any recognizable anti-PCV2 antibody
development in the unvaccinated positive controls, suggesting
that exposure of the contact pigs to vaccinated ones was suf-
ficient to transmit PCV1-2b from pig to pig and to elicit an
anamnestic immune response. Interestingly, the contact-PCV2
pigs appeared to be protected against PCV2-PRRSV-PPV
challenge, as they developed only mild microscopic PCV2-
associated lung and lymphoid lesions which did not differ from
the lesions in the Vac-0–PCV2 pigs. This finding indicates that
although the PCV1-2b vaccine is shed and transmitted from
pig to pig, it is able to induce protective immunity in nonvac-
cinated pigs. To further evaluate the degree and magnitude of
horizontal spread of the live PCV1-2b, which is an important
aspect and finding, additional experiments involving more con-
tact pigs should be conducted in the near future.
Vaccine safety was evaluated by determining the effect of
concurrent infection of pigs with the live chimeric PCV2 vac-
cine and other swine pathogens. For this objective, pigs were
vaccinated with PCV1-2b and concurrently infected with two
viral pathogens (PRRSV and PPV) that have been docu-
mented to enhance PCV2 replication and associated PCVADs
in pigs. PRRSV infection of growing pigs typically results in
respiratory disease, fever, and reduced weight gain (26). PPV
infection is normally not associated with any clinical signs in
growing pigs (2, 5). Two different time points for the coinfec-
tions were evaluated. One group was vaccinated with the chi-
meric PCV1-2b vaccine virus 4 weeks prior to PCV2-PRRSV-
PPV challenge (Vac-0–PCV2), whereas the other group was
vaccinated with the PCV1-2b vaccine virus and subsequently
inoculated with PCV2, PRRSV, and PPV on the same day
(Vac-28–PCV2). Interestingly, the amount of PCV1-2b vaccine
virus DNA among the three vaccinated groups (Vac-0, Vac-0–
PCV2, and Vac-28–PCV2) was not different at any of the time
points investigated (Table 3), indicating that concurrent infec-
tion with PRRSV and PPV did not enhance the replication of
the vaccine virus PCV1-2b, even though numerous previous
studies clearly documented that coinfection of PRRSV and
PPV with PCV2 enhanced wild-type PCV2 replication (2, 3,
16, 20, 28, 29, 39). The results suggest that the chimeric PCV2
vaccine, when used as a live-attenuated vaccine, is expected to
be safe in pigs coinfected by PRRSV and PPV. To better
evaluate the precise interactions between the different patho-
gens and the timeline of disease progression, future studies
should include higher numbers and more groups of pigs, in-
cluding pigs infected 1 to 2 days before or after vaccination.
Vaccine efficacy was determined by vaccinating pigs 28 days
prior to triple challenge using PCV2b, PRRSV, and PPV.
When Vac-0–PCV2 pigs were compared to nonvaccinated pos-
itive-control pigs, there were significantly (P  0.05) fewer
severe microscopic lesions in the lung and lymphoid tissues in
the vaccinated pigs. Moreover, no clinical disease or PCVAD-
like lesions were observed in the Vac-0–PCV2 pigs. In addi-
tion, the incidence of PCV2 viremia after challenge and the
PCV2 antigen load in tissues were significantly (P  0.05)
reduced in vaccinated animals. A protective effect of vaccina-
tion was not observed when the PCV1-2b vaccine was admin-
istered at the same time as PCV2 infection (Vac-28–PCV2);
however, this was not unexpected, as successful vaccination
with modified live vaccines requires time for the development
of an active and protective immune response. Besides the
insufficient vaccination-challenge interval (same day), it is also
possible that the acute-phase responses elicited by the different
pathogens were limiting the replication of the live chimeric
PCV2 vaccine. The main reason for including this group was to
confirm potential upregulation of the chimeric PCV2 vaccine
by simultaneous infection with PPV and PRRSV.
In this study, vaccination was done by using two routes, the
intramuscular and the intranasal routes. This approach was
mainly done to ensure that all pigs received equal amounts of
the vaccine at the same point in time and to ensure that both
the mucosal and the systemic immune systems were activated.
This approach is not likely to be practical for use in the field.
Further investigations using a route that can be used under
field conditions need to be conducted.
In summary, under the conditions of this study, we demon-
strated that a live chimeric PCV2 vaccine based upon the
PCV2b subtype was not upregulated by concurrent PPV and
PRRSV infection and that it did induce protective immunity in
a growing-pig coinfection model. To our knowledge, this is the
first efficacy study of the live PCV1-2b vaccine virus in pigs
coinfected with three common swine viral pathogens. The use
of the chimeric PCV1-2b vaccine virus to cost-effectively and
safely vaccinate large populations of pigs via the oral vaccina-
tion route appears to hold great potential.
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